Trial reportDrug design, development and therapy2025
Efficacy and Safety of Dexmedetomidine Nasal Spray as a Premedication in Patients Undergoing Fiberoptic Bronchoscopy Under Sedation: A Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effects of dexmedetomidine nasal spray on perioperative anxiety and quality of postoperative recovery in patients undergoing modified radical mastectomy for breast cancer.Frontiers in medicine · 2026Trial
- The Efficacy and Safety of Intranasal Dexmedetomidine Spray Followed by Nitrous Oxide for Paediatric Oral Procedures.International dental journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fiberoptic bronchoscopy (FB) under sedation can provoke patient discomfort, cough, and hemodynamic fluctuations. This study evaluated the efficacy and safety of dexmedetomidine nasal spray as a premedication compared to intranasal normal saline and lidocaine. Methods: A total of 90 patients scheduled for FB under sedation were randomly assigned to three groups. Group D (dexmedetomidine), Group C (control, normal saline), and Group L (lidocaine) received pre-induction nasal sprays via the same metered-dose aerosolization device. At 10 min post-spray, all patients received standard monitored anesthesia care (MAC) with preserved spontaneous ventilation (respiratory rate, RR ≥10 breaths/min; peripheral oxygen saturation, SpO Results: Group D demonstrated better overall performance. Hemodynamically, HR in Group D was lower than Group C at T Conclusion: Premedication with dexmedetomidine nasal spray in patients undergoing FB under sedation was associated with more effective suppression of procedure-induced cough, better hemodynamic stability, a lower incidence of PONV, and a faster recovery profile compared to both intranasal saline and lidocaine, without increasing respiratory depression. Consequently, dexmedetomidine nasal spray can effectively and safely enhance patient comfort and safety, and optimize the procedural conditions for the bronchoscopists.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.